Radiation Therapy as Treatment for DCIS
Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, discusses treatment options for ductal carcinoma in situ
Melvin J. Silverstein, MD, FACS, director, Breast Program Hoag Memorial Hospital, professor of surgery, Keck School of Medicine, University of Southern California, discusses treatment options for ductal carcinoma in situ (DCIS).
Clinical Pearls:
- There are about 66,000 new cases of DCIS in the United States each year
- Until recently, the standard therapy has been mastectomy or breast conservation followed by whole breast radiation therapy
- Research has suggested that 40% of DCIS patients are candidates for excision alone
- Not all patients with low grade or unaggressive DCIS should be given radiation therapy
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
December 20th 2024During a Case-Based Roundtable® event, Ian Krop, MD, and participants discussed considerations affecting first- and second-line treatment of metastatic HER2-positive breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Imlunestrant Improves PFS in ESR1-Mutant Advanced Breast Cancer
December 13th 2024The phase 3 EMBER-3 trial showed imlunestrant improved PFS over SOC endocrine therapy in ER-positive, HER2-negative advanced breast cancer with ESR1 mutations, though not significantly in the overall population.
Read More
